Posted in | Nanomedicine

Clinical Data on BIND Therapeutics’ Candidate to be Presented at AACR Annual Meeting 2014

BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced today that three poster presentations including clinical data on its lead drug candidate, BIND-014 and preclinical data on its AstraZeneca collaboration based on Barasertib (AZD1152), will be presented at the upcoming American Association of Cancer Research (AACR) meeting which takes place April 5-9, 2014 in San Diego, CA.

The prodrug Barasertib (AZD1152) is a potent selective inhibitor of the Aurora B kinase that successfully completed randomized Phase 2 studies in elderly AML patients unfit for chemotherapy. BIND and AstraZeneca have developed AccurinTM nanoparticle formulations of the active metabolite, AZD1152-hQPA, utilizing BIND’s medicinal nanoengineering platform to optimize critical properties for improved therapeutic index and schedule.

BIND-014 is a targeted polymeric nanoparticle containing the cytotoxic agent docetaxel (Taxotere). In preclinical cancer models, BIND-014 was shown to increase accumulation of docetaxel at the site of disease which translated to marked improvements in antitumor activity and tolerability. BIND-014 is currently in two Phase 2 trials in non-small cell lung cancer and metastatic castrate resistant prostate cancer.

Details of the poster presentations at AACR:

  • (Abstract #911 ): Sunday Apr 6, 2014, 1:00 p.m. - 5:00 p.m. PT, Title: “Prostate-specific membrane antigen (PSMA) expression as a potential patient selection marker in patients with refractory solid tumors administered BIND-014, a PSMA-targeted nanoparticle containing docetaxel,” Susan Low, BIND Therapeutics, Category: Clinical Research 2, Session: Predictive Biomarkers 1, Location: Hall A-E, Poster Section 37
  • (Abstract # CT210 ): Monday Apr 7, 2014, 8:00 a.m. - 12:00 p.m. PT, Title: “A phase 1 study of BIND-014, a PSMA-targeted nanoparticle containing docetaxel, administered to patients with refractory solid tumors on a weekly schedule,” Monica Mita, Samuel Oschin Comprehensive Cancer Institute, Category: Clinical Trials 1, Session: Early Phase Clinical Trials 1: Phase I, Location: Hall A-E, Poster Section 38
  • (Abstract #5409): Wednesday, April 9, 2014, 8:00 a.m. - 12:00 p.m. PT, Title: “AZD1152-hQPA Accurins: nanoparticle formulations showing extended release and the potential for improved therapeutic index,” Simon T. Barry, AstraZeneca; Jeff Hrkach, BIND Therapeutics, Category: Chemistry 11, Session: Targeted Therapies and Nanoparticle Strategies for Selective Drug Delivery, Location: Hall A-E, Poster Section 28.


Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback